JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB274913

Human CD19 knockout Raji cell line

Be the first to review this product! Submit a review

|

(0 Publication)

Human CD19 knockout Raji cell line (ab274913) available to order. Recommended control: Human wild-type Raji cell line (ab271145).

- CD19 KO validation: Next Generation Sequencing (NGS)
- Concentration: 1 million cells/vial

View Alternative Names

AW495831, Antibody deficiency due to defect in CD19, Antibody deficiency due to defect in CD19, included, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, B4, CD19 antigen, CD19 molecule, CD19_HUMAN, CVID3, Cd19 protein, Differentiation antigen CD19, Leu-12, MGC109570, MGC12802, T-cell surface antigen Leu-12

1 Images
Next Generation Sequencing - Human CD19 knockout Raji cell line (AB274913)
  • NGS

Supplier Data

Next Generation Sequencing - Human CD19 knockout Raji cell line (AB274913)

Knockout achieved by CRISPR/Cas9; X = 2 bp deletion; Frameshift : 100%

Key facts

Cell type

Raji

Species or organism

Human

Tissue

Lymphatic

Form

Liquid

form

Knockout validation

Next Generation Sequencing

Mutation description

Knockout achieved by CRISPR/Cas9 X = 2 bp deletion Frameshift: 100%

Disease

Lymphoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "NGS": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab274913-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab271145 Human wild-type Raji cell line", "number":"AB274913-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab274913 Human CD19 knockout Raji cell line", "number":"AB274913-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab274913-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab274913 Human CD19 knockout Raji cell line", "number":"AB274913-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
CD19
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Next Generation Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
-196°C|-80°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water for bath approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method. Based on cell count, seed cells in an appropriate cell culture flask at a density of 4x105 - 5x105 cells/mL(for initial passages it is recomended to culture the cells in the higher range of recomended seeding density). Seeding density is given as a guide only and should be scaled to align with individual lab schedules.
4. Incubate the culture at 37°C incubator with 5% CO2. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 4x105 cells/mL is recommended.
  • A maximum of 3x106 viable cells/mL is obtainable.
Culture medium

RPMI + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CD19 is a transmembrane protein also known as B4 or B-lymphocyte antigen CD19 with an approximate molecular weight of 95 kDa. It is expressed on the surface of B cells throughout their development from pro-B cells to mature B cells. CD19 functions mechanically as a coreceptor enhancing the sensitivity of B cell receptor (BCR) signaling. This protein plays a significant role in promoting the activation and proliferation of B cells by lowering the threshold for antigen receptor engagement.
Biological function summary

CD19 acts as an essential player in B cell signaling. CD19 integrates signals from the BCR with other coreceptors acting as a signaling hub. It participates in forming a signaling complex that includes proteins like CD21 and CD81 which further amplifies BCR-mediated signaling. This complex plays a critical role in B cell activation differentiation and survival ensuring that immune responses are efficiently mounted against pathogens.

Pathways

The CD19 protein fits into key immune response pathways such as the BCR signaling pathway and the PI3K-Akt signaling pathway. CD19 collaborates with other proteins like CD21 CD81 and PI3K within these pathways. Its interaction in the PI3K-Akt pathway for instance supports critical processes including B cell activation and homeostasis contributing to the adaptive immune response.

CD19 is connected to B cell malignancies and autoimmune diseases. B cell acute lymphoblastic leukemia (ALL) often shows aberrant CD19 expression making it a valuable target for therapeutic interventions like anti-CD19 monoclonal antibodies. Additionally overexpression or mutations of CD19 may contribute to autoimmune diseases by disrupting normal B cell regulation. CD19's connection with proteins like CD22 and CD20 in these pathological contexts highlights its relevance in developing targeted therapies.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Suspension

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com